# US 8,772,445 B2 · Production and use of antitumoral cyclodepsipeptides > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,772,445 B2 - Document ID: US8772445B2 - Status: Granted - Kind: B2 - Application number: 12/863,319 - Filed: 2008-11-20 - Published: 2011-03-31 - Granted: 2014-07-08 - Earliest claimed: 2008-01-18 - Assignees: Helmholtz-Zentrum Fuer Ozeanforschung Kiel (Geomar) - Applicants: Johannes Imhoff; Zhiguo Yu; Gerhard Lang; Jutta Wiese; Holger Kalthoff; Stefanie Klose - Inventors: Johannes Imhoff; Zhiguo Yu; Gerhard Lang; Jutta Wiese; Holger Kalthoff; Stefanie Klose - Web page: https://patentgrep.com/patent/US8772445B2 ## CPC - C07K 7/06: having 5 to 11 amino acids - A61K 38/15: Depsipeptides; Derivatives thereof - A61P 35/00: Antineoplastic agents - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract A compound having the general structure R1, R2, R3 and R4 being selected from the group consisting of a hydrogen atom (H) and a C1-C20 alkyl, and R5 being a phenyl radical. ## Claims ### Claim 1 A compound having the general structure R1, R2, R3 and R4 being selected from the group consisting of a hydrogen atom (H) and a C1-C20 alkyl, and R5 being a phenyl radical. ### Claim 2 (depends on 1) The compound according to claim 1, characterized in that at least one of R1, R2, R3 and R4 is a C1-C20 alkyl having a substituent selected from the group consisting of an acyl radical, a formyl, acetyl, trichloroacetyl, fumaryl, maleyl, succinyl, or benzoyl group, a halogen radical, an aminoalkyl group, a hydroxyl group, an ether group or a carboxyl group. ### Claim 3 (depends on 1) The compound according to claim 1 having the following formula including its diastereomeres. ### Claim 4 (depends on 1) The compound according to claim 1 having the following formula including its diastereomeres. ### Claim 5 A method for producing a compound having the general structure R1, R2, R3 and R4 being selected from the group consisting of a hydrogen atom (H) and a C1-C20 alkyl, and R5 being a phenyl radical characterized by the following steps: a. cultivating a fungus of the species Scopulariopsis and b. isolating the compound from the culture medium and/or the fungus. ### Claim 6 (depends on 5) The method according to claim 5, characterized in that the fungus is Scopulariopsis brevicaulis. ### Claim 7 A method of treating pancreatic or intestinal cancer by administering a substance having the general structure R1, R2, R3 and R4 being selected from the group consisting of a hydrogen atom (H) and a C1-C20 alkyl, and R5 being a phenyl radical as an antitumor agent. ### Claim 8 (depends on 7) The method of claim 7 wherein the substance is administered for the treatment of pancreatic cancer. ### Claim 9 (depends on 1) The compound according to claim 1, characterized in that R5 is a phenyl radical having a substituent selected from the group consisting of an acyl radical, a formyl, acetyl, trichloroacetyl, fumaryl, maleyl, succinyl, or benzoyl group, a halogen radical, an aminoalkyl group, a hydroxyl group, an ether group or a carboxyl group.